Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › palivizumab

palivizumab

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of palivizumab

8 trials tracked of palivizumab: 6 in phase 3 or 4 and 2 with published results. The most-cited published study has 184 citations.

8Trials tracked
6Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 6 Phase 2 1 Phase 1 1
  1. Phase 3 A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children Completed · 184 cited
  2. Phase 3 Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) Completed · 14 cited
  3. Phase 3 A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus Completed
  4. Phase 3 Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions Completed
  5. Phase 3 Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children Completed
  6. Phase 3 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children Completed
Show 2 more trials
  1. Phase 2 A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease Completed
  2. Phase 1 Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Monoclonal antibodies reduce RSV-related hospitalizations in premature infants with nirsevimab showing highest SUCRA values
Pediatrics Meta-analysis
Monoclonal antibodies reduce RSV-related hospitalizations in premature infants with nirsevimab showing highest SUCRA values Monoclonal antibodies reduce hospital stays for babies with RSV
This systematic review and network meta-analysis evaluated monoclonal antibodies for respiratory syncytial virus disease in premature infant…
Three different monoclonal antibodies all reduced the risk of hospitalization for premature infants with RSV infections, with one showing th…
Frontiers Jul 3, 2026
Nirsevimab and maternal RSVpreF vaccination show approximately 80% effectiveness against RSV-associated hospitalization in children
Pediatrics Meta-analysis
Nirsevimab and maternal RSVpreF vaccination show approximately 80% effectiveness against RSV-associated hospitalization in children Nirsevimab and Maternal Vaccination Show Promise for RSV Protection
This meta-analysis of 43 observational studies evaluates nirsevimab and maternal RSVpreF vaccination for preventing RSV-associated hospitali…
New data suggests that nirsevimab and maternal vaccination may significantly reduce hospitalizations caused by the respiratory syncytial vir…
Jun 26, 2026
Palivizumab reduces medically attended RSV infections in preterm infants, shows similar efficacy to nirsevimab
Pediatrics Meta-analysis
Palivizumab reduces medically attended RSV infections in preterm infants, shows similar efficacy to nirsevimab Can an older RSV drug protect healthy preterm babies from doctor visits?
A meta-analysis of three randomized, placebo-controlled studies in 2,464 healthy infants born ≤35 weeks' gestational age found palivizumab r…
An older RSV shot cuts doctor visits for preterm babies by 70%, matching newer drugs, though safety details remain unclear.
Apr 2, 2026